Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Australian biotechnology company Phosphagenics has received approval to commence its Phase I clinical trial aimed at delivering the pain relief drug, oxycodone, through the skin.
Subscribe to our email newsletter
The company is aiming to become the first to offer chronic pain sufferers a patch that provides sustained-release oxycodone into the bloodstream.
Dr Esra Ogru, executive vice president of R&D, said: “Developing its pain relief pipeline will build on the success of previous transdermal clinical trials and provide a platform for the development of many other products.”
Dr Ogru added: “With this trial, we will be using our transdermal technology to deliver oxycodone in a sustained-release formulation with the aim of treating chronic pain. Currently oxycodone is not available in a transdermal route of administration.”